APDN Applied DNA Sciences
- 0.549
- +0.037+7.15%
Applied DNA Sciences News
Applied DNA Receives Notice Of Allowance From USPTO For Patent Application 'Compositions and Methods for RNA Synthesis.'
Applied DNA Receives Notice Of Allowance From USPTO For Patent Application 'Compositions and Methods for RNA Synthesis.'
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of Its Linea(TM) IVT Platform
Patent covers the Composition of the Company's Proprietary Linea RNAP, a Core Technology Empowering the Linea IVT PlatformPatent Application Also Currently Pending in Key International Markets STONY B
Applied DNA Sciences' $12M Securities Offering and Agreement
US Equities Markets Close Mixed Tuesday as Nvidia Propels Nasdaq to Record High
US benchmark stock indexes ended mixed as Nvidia (NVDA) helped push the Nasdaq Composite to a record high, and investors focused on the macroeconomic data due in the holiday-shortened week ahead. * Mi
Top Midday Decliners
Applied DNA Sciences (APDN) said Tuesday it priced a public offering of about 9.2 million units to raise around $12 million. Shares slumped about 68%, with intraday trading volume at over 8.4 million
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) fell sharply during Tuesday's session after the company announced the pricing of a $12 million public offering.Applied DNA Sciences shares tumbled 67
Applied DNA Sciences, Sharps Technology, Akanda Among Healthcare Movers
Applied DNA Sciences Shares Resume Trade
Applied DNA Sciences Shares Resume Trade
Applied DNA Sciences Shares Halted On Circuit Breaker To The Downside, Stock Now Down -41.7%
Applied DNA Sciences Shares Halted On Circuit Breaker To The Downside, Stock Now Down -41.7%
Applied DNA Announces Pricing of $12 Million Public Offering
STONY BROOK, NY / ACCESSWIRE / May 28, 2024 / Applied DNA Sciences, Inc. , a leader in PCR-based DNA technologies, today announced the pricing of a public
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOneMedNet (NASDAQ:ONMD) stock moved upwards by 15.6% to $1.7 during Thursday's after-market session. The company's market cap stands at $40.5 million. 23andMe Holding (NASDAQ:ME) shares increas
Maxim Downgrades Applied DNA Sciences to Hold From Buy
Maxim Downgrades Applied DNA Sciences to Hold From Buy.
Applied DNA Sciences Is Maintained at Buy by HC Wainwright & Co.
Applied DNA Sciences Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Applied DNA Sciences, Adjusts Price Target To $7
HC Wainwright & Co. analyst Yi Chen maintains Applied DNA Sciences (NASDAQ:APDN) with a Buy, adjusts target to $7 from $1.5.
HC Wainwright & Co. : Maintaining the Applied DNA Sciences (APDN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $1.50 to $7.00.
HC Wainwright & Co. : Maintaining the Applied DNA Sciences (APDN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $1.50 to $7.00.
Applied DNA Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 159.84% HC Wainwright & Co. $1.5 → $7 Maintains Buy 02/09/2024 -44.32% HC Wainwright & Co. $2 →
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
STONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and the Institute of Hematology and Blood Transfusion (ÚH
Top Premarket Decliners
Barnes & Noble Education (BNED) shares were down nearly 35% in recent Monday premarket activity, extending Friday's 7.4% loss. Seritage Growth Properties (SRG) stock was 28% lower, extending Friday's
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 55.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $251.8 million. MiNK Therapeutics (NASDAQ:INK
Applied DNA Sciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 Financial Results.
Applied DNA Sciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 Financial Results.
Analysis
Price Target
No Data
